Full story: https://grafa.com/en/news/australia/bcal-diagnostics-introduces-multi-cancer-test-in-sydney-melbourne BCAL Diagnostics introduced the Avantect blood-based test in Australia to screen for eight cancer types. The company's stock remained unchanged following the product rollout announcement. The commercialisation strategy targets national expansion following initial rollouts in Sydney and Melbourne. BCAL Diagnostics (ASX:BDX) has commenced the Australian rollout of the Avantect Multi-Cancer blood-based diagnostic test in Sydney and Melbourne. The phased launch provides local patients access to non-invasive testing capable of detecting signals across eight distinct cancer types alongside organ-of-origin indicators. BCAL CEO Anne-Louise Arnett said, “The direction of cancer diagnost

Full story: https://grafa.com/en/news/australia/aurum-resources-raises-52-5m-for-project Aurum Resources secured $52.5 million in firm commitments through a single-tranche institutional placement to fund its Boundiali Project. The placement was completed at an issue price of $0.55 per share, bringing the company’s expected total cash balance to $95 million. Capital raised will accelerate early development, site access construction, land acquisition, and ongoing exploration drilling. Aurum Resources (ASX:AUE) has secured $52.5 million in firm commitments via a single-tranche institutional placement of roughly 95.5 million new shares to fund development at its Boundiali Gold Project. The issue price of $0.55 per share represents a single-tranche structure, with existing and new strategic inv

Full story: https://grafa.com/en/news/australia/qmines-intersects-broad-copper-zone-in-queensland QMines reported broad copper mineralisation at its Mt Chalmers Project. The announcement supported a 3.13% rise in the company's share price. Assays are pending for 19 holes as part of a 10,000m drilling campaign. QMines (ASX:QML) has intersected a 44m zone of copper mineralisation at its Mt Chalmers open pit in Queensland. The drill results build on the company's continuous exploration efforts aimed at expanding its regional resource footprint. QMines Exploration Manager, Tom Bartschi, said, “The 44m intersection in 26MCRD005 is a strong result, particularly the higher-grade copper intervals within it, while 26MCDD011 is also encouraging given the hole ended in mineralisation and remains unte

Full story: https://grafa.com/en/news/australia/strike-energy-selects-preferred-west-erregulla-processing-pathway Strike Energy established a processing agreement with Hancock Energy for the West Erregulla Gas Project. The transaction secures a target processing capacity net to Strike of 43.5 terajoules per day. The agreement establishes Hancock Energy’s Belisama gas processing facility as the preferred development pathway. Strike Energy (ASX:STX) has chosen Hancock Energy's Belisama Gas Processing Facility as its preferred processing pathway for the West Erregulla Project. The selection provides a clear operational framework compared to earlier standalone processing concepts considered by the joint venture. The agreement targets a processing capacity net to Strike of 43.5 terajoules per d

Full story: https://grafa.com/en/news/australia/dimerix-draws-down-17m-funding-facility Dimerix has drawn down $17 million under its non-dilutive debt facility. The funding extends the company's financial runway without diluting existing shareholder equity. Capital will directly support key clinical programmes, including the ACTION3 Phase 3 trial. Dimerix (ASX:DXB) has drawn down $17 million under a non-dilutive debt facility to fund its key clinical pipeline. The drawdown represents 50% of the overall $34 million facility that the business secured from Australian and United States lenders. "The receipt of these funds further strengthens Dimerix's financial position and supports the continued execution of our key value-driving programmes, including the ACTION3 Phase 3 study of DMX-200 and

Full story: https://grafa.com/en/news/australia/myer-posts-276-5m-loss-as-impairments-hit Myer Holdings reported a full-year statutory loss of $276.5 million. Sales grew to $4.1 billion, but the stock fell after missing profit expectations. Management points to consumer weakness and high cost-of-living pressures as key drivers. Department store retailer Myer (ASX:MYR) reported a full-year statutory loss of $276.5 million after taking a major non-cash impairment charge. The result marked a significant downturn compared to the $211 million loss recorded in the prior financial year. "Consistent with the trends we observed in June and July, trading through the early part of FY27 has remained uneven, with softer conditions experienced in August followed by improving trading momentum through Sep

Full story: https://grafa.com/en/news/australia/australian-gold-and-copper-intersects-zinc-gold-deposit Australian Gold and Copper has confirmed broad zinc-rich mineralisation with consistent gold across multiple drill holes at the Northern Evergreen prospect. The news follows a 21-hole reverse circulation drilling programme testing shallow extensions of drill hole 26DDBR017. Australian Gold and Copper stated the ongoing programme aims to expand its mineral footprint across the South Cobar Basin. Australian Gold and Copper (ASX:AGC) has intersected broad zinc-rich mineralisation carrying consistent gold grades across multiple drill holes at its Northern Evergreen deposit. The discovery follows earlier step-out drilling at the site, which had previously returned shallow high-grade intercept

Full story: https://grafa.com/en/news/australia/nufarm-targets-380m-earnings-for-fy26 Nufarm projects FY26 underlying EBITDA between $370 million and $380 million, representing 25% growth at the midpoint. Leverage is expected to fall from 2.7 times to 2.0 times by September. The company is executing factory closures and product rationalisation to secure $50 million in run-rate cost savings by the end of FY27. Agricultural chemical company Nufarm (ASX:NUF) expects its FY26 underlying EBITDA to reach between $370 million and $380 million. The projected earnings represent an approximate 25% increase compared to the prior corresponding period, driven by growth in hybrid seeds and Omega-3 platforms. Secondary operational details include plans to shut down its manufacturing facility in Alsip in

Full story: https://grafa.com/en/news/australia/tuas-full-year-net-profit-jumps-to-28-7m Tuas recorded a full-year net profit after tax of S$26 million, up from S$6.9 million last year. The company's mobile subscriber base expanded to 1.5 million, driving annual revenue up to S$187.6 million. Tuas acknowledged the intermittent use of unauthorised spectrum while setting aside up to $30 million for cybersecurity. Tuas (ASX:TUA) reported a statutory net profit after tax of S$26 million for the year ended July 31, driven by strong subscriber growth across its mobile and broadband segments. The underlying financial expansion represented a substantial jump from the preceding year when the telecommunications company generated S$6.9 million in net profit on S$151.3 million in revenue. "Simba has b

Full story: https://grafa.com/en/news/australia/iag-to-seek-public-benefits-approval-for-rac-alliance Insurance Australia Group will apply for public benefits approval following an Australian Competition and Consumer Commission merger determination. The ACCC determined in Phase 2 that the proposed alliance with the Royal Automobile Club of Western Australia should not proceed on competition grounds. IAG will pursue a public benefits determination over approximately 50 business days to secure regulatory clearance for the partnership. Insurance Australia Group (ASX:IAG) announced it will make a public benefits application to progress its proposed alliance with the Royal Automobile Club of Western Australia after the Australian Competition and Consumer Commission issued a Phase 2 determinatio

Full story: https://grafa.com/en/news/australia/asx-fails-to-meet-rba-standards-in-fy26-assessment The Reserve Bank of Australia found that ASX is still falling short of regulatory expectations regarding governance, operational resilience, and risk management. The central bank upgraded ratings for clearing and settlement divisions but noted the change does not reflect broad operational risk improvements. The regulator announced that its upcoming review will specifically examine transformation progress, financial risk models, and critical service continuity. ASX (ASX:ASX) is still falling short of regulatory expectations in governance, operational resilience, and risk management, according to the latest assessment by the Reserve Bank of Australia. The central bank noted that while the marke

Full story: https://grafa.com/en/news/australia/rba-signals-5-unemployment-target Reserve Bank of Australia governor flags higher unemployment target to cool stubborn inflation. Financial markets now price in a cash rate increase to 4.6% at the upcoming September meeting. The central bank aims to anchor long-term price expectations by absorbing excess heat from the labour market. Reserve Bank of Australia Governor Michele Bullock stated that the national unemployment rate must rise to between 4.5% and 5% to successfully rein in persistent inflation. This explicit target contrasts with previous Treasury estimates placing the non-accelerating inflation rate of unemployment at 4.25% and recent trade union calls for full employment at 4% or lower. "I think an unemployment rate between 4.5% and

Full story: https://grafa.com/en/news/united-states/celldex-reports-phase-3-csu-trial-results Celldex Therapeutics (NASDAQ:CLDX) reported positive Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 results for barzolvolimab in chronic spontaneous urticaria. Both trials met their primary endpoint, showing greater reductions in weekly urticaria activity scores compared with placebo at Week 12. Celldex stated that it plans to submit a Biologics License Application for barzolvolimab in 2027. Celldex Therapeutics (NASDAQ:CLDX) reported positive topline results from two Phase 3 trials evaluating barzolvolimab in adults with chronic spontaneous urticaria. The EMBARQ-CSU1 and EMBARQ-CSU2 studies met the primary endpoint, with barzolvolimab showing greater reductions in weekly urticaria activity scores at Week 12

Full story: https://grafa.com/en/news/united-states/amgen-reports-sjogrens-drug-trial-success Amgen (NASDAQ:AMGN) said its experimental drug dazodalibep met the main goal in a late-stage trial for Sjogren’s disease. The drug showed statistically significant and clinically meaningful improvement in disease activity at Week 48 compared with the study’s control group. Amgen plans to present detailed trial data at an upcoming medical meeting as it continues development of dazodalibep. Amgen (NASDAQ:AMGN) said its experimental drug dazodalibep met the primary goal in a late-stage trial evaluating treatment for Sjogren’s disease. The Phase 3 study showed statistically significant and clinically meaningful improvement in disease activity at Week 48 among patients treated with dazodalibep. Amgen r

Full story: https://grafa.com/en/news/united-states/filana-rises-after-fda-lifts-simufilam-hold Filana Therapeutics (NASDAQ:FLNA) shares rose after the FDA lifted a clinical hold on its experimental epilepsy drug simufilam. The stock increased 30% to $0.96 in premarket trading following the regulatory update. Filana stated that the FDA decision allows the company to begin a Phase 2 study evaluating simufilam in patients with epilepsy linked to tuberous sclerosis complex. Filana Therapeutics (NASDAQ:FLNA) shares rose after the U.S. Food and Drug Administration lifted a clinical hold on its experimental drug simufilam for epilepsy linked to tuberous sclerosis complex. The shares increased 30% to $0.96 in premarket trading after Filana announced that the FDA decision allows its mid-stage clin

Full story: https://grafa.com/en/news/united-states/compass-shares-fall-after-fda-tovecimig-feedback Compass Therapeutics (NASDAQ:CMPX) shares fell after the U.S. FDA recommended a new trial before a marketing application for tovecimig. The stock declined 40.8% to $1.51 in premarket trading following the regulatory update. Compass stated that it disagrees with the need for another trial and plans to continue discussions with the FDA. Compass Therapeutics (NASDAQ:CMPX) shares declined after the U.S. Food and Drug Administration recommended an additional trial before the company submits a marketing application for tovecimig. The shares fell 40.8% to $1.51 in premarket trading after the company disclosed the FDA’s recommendation regarding the experimental cancer treatment. The FDA recommendat

Full story: https://grafa.com/en/news/united-states/oil-prices-fall-as-gulf-supply-risks-ease Brent and WTI crude futures fell to two-week lows as concerns over Gulf supply disruptions eased. Brent November futures declined 2.1% to $98.23 per barrel, while WTI November futures fell 2.55% to $90.01 per barrel. Markets reacted to Iran’s comments on a possible Strait of Hormuz reopening and Saudi Arabia’s planned return of exports from Yanbu port. Oil prices declined to two-week lows on Tuesday as expectations for Gulf supply recovery improved following developments involving Iran and Saudi Arabia. Brent crude November futures fell $2.11, or 2.1%, to $98.23 per barrel, while WTI November futures declined $2.36, or 2.55%, to $90.01 per barrel. Iranian officials said the country could reopen th

Full story: https://grafa.com/en/news/united-states/pharming-leniolisib-phase-2-primary-immunodeficiency-results Pharming (NASDAQ:PHAR) reported positive Phase II topline results for leniolisib in genetically identifiable primary immunodeficiencies linked to PI3Kδ signaling. The study showed reductions in lymphoproliferative disease measures, including a mean 26.4% reduction in spleen volume. Additional data will be presented at the ESID 2026 meeting. Pharming Group (NASDAQ:PHAR) announced positive topline results from a Phase II study evaluating leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) associated with immune dysregulation caused by PI3Kδ signaling abnormalities. The study was accepted as a late-breaking abstract for presentation at the 2026 Eu

Full story: https://grafa.com/en/news/united-states/here-group-here-fiscal-2026-results-share-buyback Here Group (NASDAQ:HERE) reported fiscal 2026 revenue of RMB596.8 million, driven by its first full year of pop toy business operations. The company recorded a net loss impacted by a goodwill impairment charge related to the Letsvan acquisition. Here Group announced a $20 million share repurchase program and a management change. Here Group (NASDAQ:HERE) reported unaudited financial results for the fourth quarter and full fiscal year ended June 30, 2026, highlighting revenue growth from its expanding pop toy business and announcing corporate leadership changes. Fourth-quarter revenue totaled RMB127.7 million, representing a 22.5% sequential decline but a 94.1% increase compared with the sam